Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
By R. Pratley, V. Aroda, I. Lingvay, J. Lüdemann, C. Andreassen, A. Navarria, A. Viljoen. The Lancet Diabetes and Endocrinology, 2018
662 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/9804a6d7077c5181cb3bf2700eb80ccacfe94b54
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, methodology): “All data are from clinical trials reporting head-to-head comp vs liraglutide [37], lixisenatide vs liraglutide [38], exenatide once-weekly vs liraglutide [39], vs dulaglutide [42], and oral semaglutide vs liraglutide [43]) on a background of oral glucos equations to calculate common means and their ”
- Glucagon-like peptide 1 (GLP-1) (2019, background): “8% after 40 wk of treatment in T2DM patients [898].”